Navigation Links
Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
Date:10/1/2010

PASADENA, Calif., Oct. 1 /PRNewswire/ -- Maven Biotechnologies today announced that the company has been awarded $1.96 million by the National Institute for Allergy and Infectious Disease (NIAID), part of the NIH, to support the commercialization of their LFIRETM imaging technology for label-free protein microarrays and cell-based assays. The highly competitive grant was awarded to Maven through the federal stimulus package initiative for Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN).

(Logo: http://photos.prnewswire.com/prnh/20101001/LA75512LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101001/LA75512LOGO)

"Maven welcomes the support of the NIH to bring our platform to market," says Chief Technology Officer David Ralin. "LFIRETM's label-free, multiplexed capabilities and inherent simplicity will directly benefit our customers, delivering better results in less time and with lower costs." Target applications for the technology include - but are not limited to - immunoassays in the research and diagnostics markets, cell-based studies, high-throughput pharmaceuticals screening and the established label-free applications in biomolecular interaction analysis.

Chief Engineering Officer Jeffrey Chongsathien M.A. Cantab. adds, "We look forward to creating a robust, flexible and modular product portfolio of laboratory instrumentation and consumables, built on LFIRETM." The initial instrument will be a desktop microplate reader, with a set of 'alpha' evaluation units expected to be completed in the first quarter of 2011 and made available for use by key academic collaborators and strategic industry partners.

Company Founder and CEO William Rassman M.D. noted that the grant will 'jump-start' the commercialization of the product and will be the forerunner of other funding events.

About Maven Biotechnologies

Maven Biotechnologies (www.mavenbiotech.com) is a privately-held biotechnology company located in Pasadena, CA. The company has developed LFIRE™ [pronounced: el - fire] - a flexible, cost-effective, high density imaging technology for the multiplexed, quantitative, label-free, real-time characterization of biomarker binding reactions. The platform addresses applications in biomedical research, drug discovery, immunodiagnostics, biodefense, biological manufacturing and point-of-care. Maven holds 14 granted US and international patents.


'/>"/>
SOURCE Maven Biotechnologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
2. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
3. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
4. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
5. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
6. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
7. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
8. Reportlinker Adds Nanobiotechnologies- Applications, Markets and Companies
9. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
10. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
11. Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
Breaking Biology News(10 mins):